test
Home / NDTV Profit / News / Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix

Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix

- ,
The brokerage recommends a 'Buy' with a target price of Rs 1,823 based on 45 times PE /multiple (50 times earlier).

from NDTV Profit https://ift.tt/miACj9Z
Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix Reviewed by aamira sultan on November 12, 2024 Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.